NCT03955042View on ClinicalTrials.gov

Pemetrexed for the Treatment of Chordoma

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 6, 2019

Primary Completion Date

July 27, 2022

Study Completion Date

January 18, 2023

Conditions
Chordoma
Interventions
DRUG

Pemetrexed

Pemetrexed 900 mg/m\^2 on Day 1 of each 21-day cycle. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.

Trial Locations (1)

90404

John Wayne Cancer Institute, Santa Monica

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Chordoma Foundation

OTHER

lead

Saint John's Cancer Institute

OTHER

NCT03955042 - Pemetrexed for the Treatment of Chordoma | Biotech Hunter | Biotech Hunter